@media (max-width: 768px) {
                .image-container {
                    width: 100% !important;
                    float: none !important;
                    margin: 0 0 1rem 0 !important;
                }
            }
        



Image source: The Mo

Halozyme (HALO) Q3 2026 Earnings Call Transcript

Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the State Street SPDR Portfolio Intermediate Term Treasury ETF, which added 43,699,664 units, or a 11.1% increase week over week.  

And on a percentag

SPTI, AZTD: Big ETF Inflows  

(RTTNews) - Halozyme Therapeutics, Inc. (HALO) announced that the specialised Dutch patent court of The Hague found that Merck & Co., Inc. (MRK)  infringed Halozyme's EP622 patent through its subcutaneous formulation of Keytruda.

Halozyme Wins Dutch Patent Case Against Merck Over Keytruda SC 

(RTTNews) - Halozyme Therapeutics, Inc. (HALO) announced an expansion of its global collaboration with argenx SE(ARGX), granting the company exclusive access to its ENHANZE drug-delivery technology for two additional therapeutic targets, increasing the total number of licensed ta

Halozyme, Argenx Expand ENHANZE Collaboration With Two Additional Targets 

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers.

Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors. Mr. Daly is a highly respected biopharmaceutical executive with more than three decades of commercial leadership experience and a proven track record of shaping the profile of innovative therapies resulting in highly successful launches of respiratory, oncology and immunology therapies.

Halozyme Announces Appointment of Jim Daly to its Board of Directors

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Halozyme Therapeutics, Inc. News